Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdfAccessed June 18, 2014
   Google Scholar
• Global Initiative for AsthmaGlobal strategy for asthma management and prevention Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdfAccessed June 18, 2014
   Google Scholar
• PageCCazzolaMBifunctional drugs for the treatment of asthma and chronic obstructive pulmonary diseaseEur Respir J20144447548224696121
   PubMed Web of Science ®Google Scholar
• FroisCWuEQRaySColiceGLInhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterolClin Ther2009312779280320110019
   PubMed Web of Science ®Google Scholar
• TammMRichardsDHBeghéBFabbriLInhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practiceRespir Med2012106Suppl 1S9S1923273165
   PubMed Web of Science ®Google Scholar
• McKeageKKeamSJSalmeterol/fluticasone propionate: a review of its use in asthmaDrugs2009691799182819719334
   PubMed Web of Science ®Google Scholar
• ChungKFSalmeterol/fluticasone combination in the treatment of COPDInt J COPD20061235242
   Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20021661084109112379552
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet200336144945612583942
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356755789
   Web of Science ®Google Scholar
• CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med200817833233818511702
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest200312483484312970006
   PubMed Web of Science ®Google Scholar
• BatemanEDBousheyHABousquetJGOAL Investigators GroupCan guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL studyAm J Respir Crit Care Med200417083684415256389
   PubMed Web of Science ®Google Scholar
• BatemanEDBousquetJBusseWWon behalf of the GOAL Steering Committee and InvestigatorsStability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) studyAllergy20086393293818588561
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseDiagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS)52014 Available from: http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdfAccessed March 7, 2015
   Google Scholar
• LopezADMurrayCCThe global burden of disease, 1990–2020Nat Med1998411124112439809543
   PubMed Web of Science ®Google Scholar
• Respiratory Diseases Branch of Chinese Medical AssociationA national guideline for the diagnosis, management, and prevention of chronic obstructive pulmonary disease in ChinaChin J Tuberc Respir Dis200730817
   Google Scholar
• ZhongNWangCYaoWPrevalence of chronic obstructive pulmonary disease in China: a large, population-based surveyAm J Respir Crit Care Med200717675376017575095
   PubMed Web of Science ®Google Scholar
• Chinese Ministry of HealthThe top ten disease specific rates and causes of death among urban and rural residents Available from: http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkat/ptjnj/20008/42835.htmAccessed June 1, 2014
   Google Scholar
• FangXWangXBaiCCOPD in China: the burden and importance of proper managementChest201113992092921467059
   PubMed Web of Science ®Google Scholar
• LinHHMurrayMCohenTColijnCEzzatiMEffects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling studyLancet20083721473148318835640
   PubMed Web of Science ®Google Scholar
• LuPZhuYChenPVulnerability of patients with chronic obstructive pulmonary disease according to gender in ChinaInt J COPD20127825832
   Google Scholar
• LiQHsiaJYangGPrevalence of smoking in China in 2010N Engl J Med20113642469247021696322
   PubMed Web of Science ®Google Scholar
• YinPZhangMLiYJangYZhaoWPrevalence of COPD and its association with socioeconomic status in China: findings from China Chronic Disease Risk Factor SurveillanceBMC Public Health20111158621781320
   PubMed Web of Science ®Google Scholar
• ToTStanojevicSMooresGGlobal asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health20121220422429515
   PubMed Web of Science ®Google Scholar
• LeungRWongGLauJPrevalence of asthma and allergy in Hong Kong schoolchildren: an ISAAC studyEur Respir J1997103543609042632
   PubMed Web of Science ®Google Scholar
• WongGWKoFWHuiDSFactors associated with difference in prevalence of asthma in children from three cities in China: multicentre epidemiological surveyBMJ200432948615331473
   PubMed Web of Science ®Google Scholar
• International Study of Asthma and Allergies in Childhood Steering CommitteeWorldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczemaLancet199835111251132
   Web of Science ®Google Scholar
• BrooksCPearceNDouwesJThe hygiene hypothesis in allergy and asthma: an updateCurr Opin Allergy Clin Immunol201313707723103806
   PubMed Web of Science ®Google Scholar
• HeQYZhouXXieCMImpact of chronic obstructive pulmonary disease on quality of life and economic burden in Chinese urban areasZhonghua Jie He He Hu Xi Za Zhi200932253257 Chinese19576036
   PubMedGoogle Scholar
• LouPZhuYChenPVulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional studyBMC Public Health20121228722521113
   PubMed Web of Science ®Google Scholar
• Respiratory Diseases Branch of the Chinese Medical AssociationBronchial asthma therapeutic guidelines. Definition, diagnosis, treatment, education and management of bronchial asthmaChin J Tuberc Respir Dis200326132138 Chinese
   Google Scholar
• LiZPHuangJQTangKJRetrospective studies on 713 cases chronic obstructive pulmonary diseaseZhonghua Liu Xing Bing Xue Za Zhi200324722724 Chinese14521798
   PubMedGoogle Scholar
• ShenNYaoWZZhuHPatient’s perspective of chronic obstructive pulmonary disease in Yanqing county of BeijingZhonghua Jie He He Hu Xi Za Zhi200831206208 Chinese18785520
   PubMedGoogle Scholar
• ZhangRBHeQYAwareness of knowledge of COPD by doctors in district and community hospitalsChin J Prev Control Chronic Dis2009176163 Chinese
   Google Scholar
• HeQYZhouXXieCMThe investigation of the treatment conditions in stable COPD patients in partial cities in People’s Republic of ChinaChin J Pract Intern Med200929354357 Chinese
   Google Scholar
• SuNLinJChenPEvaluation of asthma control: a questionnaire-based survey in ChinaChin Med J (Engl)20141272030203624890147
   PubMed Web of Science ®Google Scholar
• BarnesNCQiuYSPavordIAnti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung diseaseAm J Respir Crit Care Med200617373674316424444
   PubMed Web of Science ®Google Scholar
• SinDDLacyPYorkEEffects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200417076076515229100
   PubMed Web of Science ®Google Scholar
• SinDDManSFPMarciniukDDfor the ABC (Advair, Biomarkers in COPD) InvestigatorsThe effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20081771207121418310480
   PubMed Web of Science ®Google Scholar
• YangLMaQYaoWRelationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+ regulatory T cells in COPDRespir Res20111214222032685
   PubMed Web of Science ®Google Scholar
• TangYJWangKYuanTSalmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary diseaseChin Med J (Engl)20101231652165720819623
   PubMed Web of Science ®Google Scholar
• DuYWangWYangWInterleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary diseaseChin Med J (Engl)20141271613161824791863
   PubMed Web of Science ®Google Scholar
• CurrieGPSyme-GrantNJMcFarlaneLCCareyFALipworthBJEffects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthmaAllergy20035860260712823118
   PubMed Web of Science ®Google Scholar
• PavordIWoodcockAParkerDSOLTA Study GroupSalmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthmaRespir Res200786717897478
   PubMed Web of Science ®Google Scholar
• ChenPZhaoHTSunL[The efficacy of half of the Global Initiative for Asthma recommended dose of inhaled corticosteroids in the management of Chinese asthmatics]. ChineseZhonghua Jie He He Hu Xi Za Zhi2005287458463 Chinese16115394
   PubMedGoogle Scholar
• BoydGMoriceAHPounsfordJCAn evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)Eur Respir J1997108158219150318
   PubMed Web of Science ®Google Scholar
• UlrikCSEfficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover studyThorax1995507507547570409
   PubMed Web of Science ®Google Scholar
• FergusonGAnzuetoAFeiREffect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbationsRespir Med20081021099110818614347
   PubMed Web of Science ®Google Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200717514414917053207
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJACalverleyPMAdherence to inhaled therapy, and mortality and hospital admission for COPDThorax20096493994319703830
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• ZhengJPYangLWuYMThe efficacy and safety of combination salmeterol (50 μg)/fluticasone propionate (500 μg) inhalation twice daily via accuhaler in Chinese patients with COPDChest20071321756176317951625
   PubMed Web of Science ®Google Scholar
• ChengSSuKWangKPengDYangPChronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumoniaDrug Des Devel Ther20148601607
   Web of Science ®Google Scholar
• HananiaNCraterGMorrisABenefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPDRespir Med20121069110122040533
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKFergusonDTiotropium in combination with placebo, salmeterol, or fluticasone/salmeterol for treatment of COPD: a randomized trialAnn Intern Med200714654555517310045
   PubMed Web of Science ®Google Scholar
• SinghDBrooksJHaganGCahnAConnorJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax20086359259818245142
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med20143711285129425196117
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• ShapiroGShapiroGLumryWA Combined salmeterol 50 mg and fluticasone propionate 250 mg in the Diskus device for the treatment of asthmaAm J Respir Crit Care Med200016152753410673196
   PubMed Web of Science ®Google Scholar
• KavuruMMelamedJGrossGSalmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trialJ Allergy Clin Immunol20001051108111610856143
   PubMed Web of Science ®Google Scholar
• AubierMPietersWSchlosserNSalmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthmaRespir Med19999387688410653049
   PubMed Web of Science ®Google Scholar
• WoodcockABleeckerERLötvallJEfficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trialChest20131441222122923846316
   PubMed Web of Science ®Google Scholar
• You-NingLHumphriesMDuXWangLJiangJEfficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroidsInt J Clin Pract20055975475915963199
   PubMed Web of Science ®Google Scholar
• DahlRChuchalinAGorDEXCEL: a randomized trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthmaRespir Med20061001152116216675212
   PubMed Web of Science ®Google Scholar
• ZhongNSZhengJPCaiBQSalmeterol/fluticasone propionate in a single inhaler is superior to budesonide alone in control of Chinese asthmatic adultsClin Drug Investig200424583594
   Web of Science ®Google Scholar
• NelsonHBusseWKerwinEFluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukastJ Allergy Clin Immunol20021061088109511112891
   PubMed Web of Science ®Google Scholar
• RingdalNElirazAPruzinecPThe salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthmaRespir Med20039723424112645830
   PubMed Web of Science ®Google Scholar
• GaoJFengCPengMMaYWangBMontelukast improves air trapping, not airway remodeling, in patients with moderate-to-severe asthma: a pilot studyChin Med J (Engl)20131262229223423786930
   PubMed Web of Science ®Google Scholar
• BarnesPJTheophylline: new perspectives for an old drugAm J Respir Crit Care Med200316781381812623857
   PubMed Web of Science ®Google Scholar
• BarnesPTheophyllinePharmaceuticals (Basel)20103725747
   Google Scholar
• NieHZhangGLiuMEfficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthmaRespir Med201310734735423290154
   PubMed Web of Science ®Google Scholar
• WangYWangCZLinKXComparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate to severe asthmaRespirology20051018919515823184
   PubMed Web of Science ®Google Scholar
• CrimCCalverleyPMAAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J20093464164719443528
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnestPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax2013681029103624130228
   PubMed Web of Science ®Google Scholar
• O’ByrnePPedersenSCarlssonLRisks of pneumonia in patients with asthma taking inhaled corticosteroidsAm J Respir Crit Care Med201118358959520889908
   PubMed Web of Science ®Google Scholar
• ChorãoPPereiraAMFonsecaJAInhaler devices in asthma and COPD – an assessment of inhaler technique and patient preferencesRespir Med201410896897524873873
   PubMed Web of Science ®Google Scholar
• LiHChenYZhangZDongXZhangGZhangHHandling of Diskus dry powder inhaler in Chinese chronic obstructive pulmonary disease patientsAerosol Med Pulm Drug Deliv201427219227
   Web of Science ®Google Scholar
• MahlerDAWatermanLAGiffordAHPrevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhalerJ Aerosol Med Pulm Drug Deliv20132617417923025451
   PubMed Web of Science ®Google Scholar